Breakthrough Partnership Aims to Revolutionise Gastrointestinal Cancer Treatment

2026-06-15 biotech

Brussels, Monday 15 June 2026
Lonza and Antharis Therapeutics join forces in an exclusive deal to develop cutting-edge dual-payload antibody-drug conjugates (ADCs) for gastrointestinal cancers, potentially transforming patient outcomes. This collaboration, announced on 15 June 2026, merges Lonza’s advanced ADC technology with Antharis’s oncology expertise, promising to accelerate the creation of highly targeted therapies for unmet medical needs.

The Science Behind Dual-Payload ADCs

Antibody-drug conjugates (ADCs) represent a paradigm shift in cancer treatment, combining the targeting precision of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs [1]. The dual-payload approach, central to this partnership, addresses a critical limitation of conventional ADCs: tumour heterogeneity. Gastrointestinal cancers, particularly colorectal and gastric cancers, exhibit significant molecular diversity both between patients and within individual tumours [2]. Dual-payload ADCs can simultaneously target multiple cancer pathways, potentially overcoming resistance mechanisms that limit single-agent therapies [1]. Lonza’s proprietary technology enables site-specific conjugation of two distinct payloads to a single antibody, creating a more versatile therapeutic platform [1]. This innovation builds upon the success of first-generation ADCs like trastuzumab emtansine (Kadcyla®), which demonstrated the clinical viability of targeted cytotoxic delivery [3].

Strategic Division of Expertise

The collaboration establishes a clear division of labour that leverages each company’s core competencies. Lonza, a global leader in pharmaceutical manufacturing, will provide its proprietary dual-payload ADC technology platform and handle the manufacturing of critical components including payloads and linkers [1]. Antharis Therapeutics, a Belgian biopharmaceutical company specialising in oncology, retains full responsibility for research and development, clinical trial execution, and eventual commercialisation [1]. This structure allows Antharis to maintain control over its intellectual property while accessing Lonza’s established manufacturing infrastructure [1]. The agreement includes financial terms where Lonza is eligible for upfront payments, development milestones, and royalties on future sales, creating a mutually beneficial economic model [1]. This partnership structure reflects a growing trend in the biopharmaceutical industry, where specialised firms collaborate to accelerate drug development timelines while sharing financial risks [GPT].

Clinical Development Timeline and Market Potential

Antharis Therapeutics’ lead dual-payload ADC programme targeting gastrointestinal cancers is positioned to enter clinical trials in the near term, with the first patient expected to be dosed in Q1 2027 [1]. Gastrointestinal cancers represent a significant unmet medical need, with colorectal cancer alone accounting for approximately 1.9 million new cases and 935,000 deaths annually worldwide as of 2020 [4]. The global ADC market, valued at $7.2 billion in 2023, is projected to reach $31.2 billion by 2030, growing at a compound annual growth rate of 333.333% [5]. Within this market, gastrointestinal cancer therapeutics represent a particularly attractive segment due to the high prevalence and limited treatment options for advanced-stage disease [4]. The dual-payload approach specifically targets multi-drug resistance, a major challenge in gastrointestinal oncology where 40-50% of patients develop resistance to first-line therapies [6].

Regulatory Landscape and Competitive Positioning

The partnership enters a regulatory environment that has become increasingly favourable for ADCs. The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have established accelerated approval pathways for oncology therapeutics addressing unmet medical needs [7]. In 2023, the FDA approved 12 new molecular entities for cancer treatment, of which 3 were ADCs, demonstrating the growing acceptance of this therapeutic class [8]. The dual-payload approach, while innovative, faces potential regulatory scrutiny regarding safety profiles and manufacturing complexity [alert! ‘regulatory requirements for multi-payload biologics remain less established than for single-agent therapies’]. Competitively, Antharis and Lonza will face established players like Seagen (now part of Pfizer) and Daiichi Sankyo, which dominate the ADC market with approved products like Adcetris® and Enhertu® [9]. However, the gastrointestinal cancer segment remains less crowded, with only one FDA-approved ADC (Padcev® for urothelial cancer) showing potential in gastrointestinal indications [10].

Broader Implications for Benelux Biotech Innovation

This collaboration underscores the growing importance of the Benelux region in the global biotechnology landscape. Belgium, home to Antharis Therapeutics, has emerged as a hub for antibody-based therapeutics, with over 200 biotech companies and 15,000 employees in the sector as of 2025 [11]. The partnership leverages Belgium’s strong academic-industry interface, particularly in oncology research, with institutions like KU Leuven and the VIB (Flanders Institute for Biotechnology) contributing to the country’s biotech ecosystem [12]. This deal follows a series of high-profile biotech partnerships in the region, including Galapagos NV’s collaboration with Gilead Sciences and argenx’s global expansion [13]. The Lonza-Antharis agreement specifically highlights the region’s strength in precision medicine, with Belgian companies receiving €1.2 billion in venture capital funding for life sciences in 2025, a 35% increase from 2023 [34.831][14]. This funding environment has enabled the development of specialised firms like Antharis, which focuses exclusively on antibody-based oncology therapeutics [1].

Technological Challenges and Future Directions

The development of dual-payload ADCs presents significant technological challenges that this partnership aims to address. Key hurdles include maintaining antibody stability with multiple payloads, achieving optimal drug-to-antibody ratios, and ensuring consistent manufacturing at scale [15]. Lonza’s proprietary technology addresses these challenges through site-specific conjugation methods that preserve antibody integrity while enabling precise payload attachment [1]. The partnership will also explore novel linker technologies designed to enhance payload release within tumour microenvironments while minimising systemic toxicity [1]. Looking ahead, both companies have indicated interest in expanding the dual-payload platform beyond gastrointestinal cancers. Antharis’s pipeline includes programmes targeting breast and lung cancers, while Lonza continues to develop its ADC technology for additional therapeutic areas [1]. The success of this collaboration could establish a new standard for multi-payload biologics, potentially influencing the broader field of targeted cancer therapeutics [alert! ‘clinical outcomes from this partnership remain unproven until trial data becomes available’].

Sources & Ecosystem Partners

antibody-drug conjugates oncology therapeutics